Personal information

Other IDs

Scopus Author ID: 57217880377

Activities

Collapse all

Employment (1)

IRCCS Humanitas Research Hospital: Rozzano, IT

(Oncology and Hematology)
Employment
Source: Self-asserted source
Eleonora Calabretta

Works (8)

DLBclass: A Probabilistic Molecular Classifier to Guide Clinical Investigation and Practice in DLBCL

Blood Journal
2024-12-16 | Journal article
DOI: 10.1182/blood.2024025652
Contributors: Björn Chapuy; Timothy R. Wood; Chip Stewart; Andrew J. Dunford; Kirsty Wienand; Sumbul J. Khan; Nazli Serin; Meng Wang; Eleonora Calabretta; Joji Shimono et al.
Source: check_circle
Crossref

Baseline circulating tumour DNA and interim PET predict response in relapsed/refractory classical Hodgkin lymphoma

British Journal of Haematology
2024-02 | Journal article
DOI: 10.1111/bjh.19162
Contributors: Eleonora Calabretta; Martina di Trani; Francesco Corrado; Martina Sollini; Vanessa Cristaldi; Fabrizio Marino; Lodovico Terzi di Bergamo; Alessio Bruscaggin; Maria Cristina Pirosa; Stefania Bramanti et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma

Blood
2022 | Journal article
DOI: 10.1182/blood.2021014663
EID:

2-s2.0-85135069541

Part of ISSN: 15280020 00064971
Contributors: Calabretta, E.; Hamadani, M.; Zinzani, P.L.; Caimi, P.; Carlo-Stella, C.
Source: Self-asserted source
Eleonora Calabretta via Scopus - Elsevier

Chemotherapy after PD‐1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics

British Journal of Haematology
2022-07 | Journal article
DOI: 10.1111/bjh.18183
Contributors: Eleonora Calabretta; Anna Guidetti; Francesca Ricci; Martina Di Trani; Chiara Monfrini; Massimo Magagnoli; Stefania Bramanti; Davide Maspero; Lucia Morello; Michele Merli et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes

Expert Opinion on Therapeutic Targets
2021 | Journal article
DOI: 10.1080/14728222.2021.1944101
EID:

2-s2.0-85108797607

Part of ISSN: 17447631 14728222
Contributors: Richardson, E.; García-Bernal, D.; Calabretta, E.; Jara, R.; Palomo, M.; Baron, R.M.; Yanik, G.; Fareed, J.; Vlodavsky, I.; Iacobelli, M. et al.
Source: Self-asserted source
Eleonora Calabretta via Scopus - Elsevier

COVID‐19‐induced endotheliitis: emerging evidence and possible therapeutic strategies

British Journal of Haematology
2021-04 | Journal article
DOI: 10.1111/bjh.17240
Contributors: Eleonora Calabretta; Jose M. Moraleda; Massimo Iacobelli; Ruben Jara; Israel Vlodavsky; Peter O’Gorman; Antonio Pagliuca; Clifton Mo; Rebecca M. Baron; Alessio Aghemo et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

The Many Facets of CD38 in Lymphoma: From Tumor-Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy

Cells
2020 | Journal article
DOI: 10.3390/cells9040802
EID:

2-s2.0-85089712395

Part of ISSN: 20734409
Contributors: Calabretta, E.; Carlo-Stella, C.
Source: Self-asserted source
Eleonora Calabretta via Scopus - Elsevier

Immune and inflammatory cells of the tumor microenvironment represent novel therapeutic targets in classical hodgkin lymphoma

International Journal of Molecular Sciences
2019 | Journal article
DOI: 10.3390/ijms20215503
EID:

2-s2.0-85074616107

Part of ISSN: 14220067 16616596
Contributors: Calabretta, E.; D’amore, F.; Carlo-Stella, C.
Source: Self-asserted source
Eleonora Calabretta via Scopus - Elsevier
How many people are using ORCID?